Introduction
There is increasing concern that many published results of randomised trials are biased by selective reporting of trials with positive results, and by researchers, often inadvertently, selectively reporting nominally statistically significant outcomes. 1 This latter practice has been called P-hacking. There are several ways researchers can fall foul of P-hacking by misreporting the true effect sizes in their studies. These include monitoring data accrual and stopping a trial if an analysis yields a significant P-value or using different statistical analyses, data eligibility criteria, outcomes and treatment groups before deciding which to report post-analysis. Double blinding and trial registration mitigate P-hacking by researchers pre-specifying their primary outcome and analysis plans, only conducting the analyses when the trial has ended and the code is broken. 2 Systematic reviewers are equally at risk if they fail to pre-specify their primary outcomes instead choosing to publish when the data look interesting. They can try to minimise the problem by including all available trials, and registering protocols before starting work, but the former policy risks including more low quality biased trial data and the latter is difficult in a mature field where the results of the major trials and reviews are already widely known. 2 Meta-analyses are only as good as those data they use, but their results influence treatment decisions, health policy and the direction of future research. P-hacking is important because the publication of false positives leads to the adoption of treatments which are ineffective to patients.
Studies of progestogens to prevent pregnancy complications provide a good setting to measure this effect because there have been many trials and at least twenty-nine metaanalyses. The aim of this work was to compare the findings all progestogen trials and systematic reviews with those of trials with pre-registered primary outcomes which avoided selective outcome reporting to explore the impact of Phacking.
Methods
The review was conducted following the PRISMA statement, 3 and the protocol prospectively registered with PROSPERO CRD42016035303.
Search strategy
We searched PubMed, the Cochrane Library and World Health Organisation recognised publicly-registered trials registries 4 from inception to August 2016 for terms related to progestogen, pregnancy and trials (Appendix S1). Two authors (MP and JT) independently conducted the first screening of potentially relevant records based on titles and abstract and then independently performed the final selection of included trials based on full text evaluation. Citation tracking was also performed on included studies and relevant systematic reviews. Consensus between the two reviewers was used to resolve any disagreement.
Study selection
The total study group This included all systematic reviews with meta-analyses of double-blind randomised controlled trials comparing the efficacy of progestogens versus placebo in pregnancy to improve any pregnancy outcome. We analysed all outcomes reported by these systematic reviews. For individual trials we identified all trials included in at least one metaanalysis, and analysed all outcomes for which data had been included in at least one meta-analysis.
The preregistered trial outcome group We included trials which were prospectively listed in a World Health Organisation recognised publicly-registered trials registry with a predefined primary outcome, and which either achieved their pre-specified sample size, or were both double blind, and failed to achieve their sample size for logistical reasons unrelated to the trial result. The primary outcome had to be included in the trial report. Trials were excluded if they were not registered or registered late. There were no restrictions for languages or publication date.
Data extraction and quality assessment
Two reviewers (MP and JT) independently assessed the reviews and trials for inclusion. For systematic reviews three reviewers (MP, RH and NA) extracted all outcomes, the number of trials used for each meta-analysis, whether the point estimate favoured progesterone or placebo and if the 95% confidence interval crossed 1. For RCTs study characteristic data were extracted by two reviewers (MP, and JT) (details of participants, intervention, registered primary outcome with intention to treat analysis and the number of secondary outcomes) for the included trials. Two reviewers (MP and JGT) compared each manuscript with the trial registration and excluded trials that did not reported the registered primary outcome. For trials with dichotomous outcomes we extracted the number of participants and events in the progestogen and control groups. For trials with a continuous primary outcome we extracted means, standard deviations, and sample sizes for the preregistered primary outcome measure. Consensus was used to resolve any disagreement.
Data analysis
For trials, we ensured consistency in direction of effect by converting the primary outcomes. For example, "reaching 24 weeks with a live baby" was converted to "failing to reach 24 weeks with a live birth". Summary measures used were risk ratio and mean difference using a random effects model. For trials reporting only the median and interquartile range; we assumed that the former equalled the mean and that the standard deviation was 1.35 times the latter. RevMan version 5.3. (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark) was used to generate figures and summaries.
Results

Study selection
Our search results yielded 3753 records, and after excluding duplicates we screened 2467 titles and abstracts ( Figure 1 ). This process finally revealed 194 relevant studies.
Systematic reviews
We identified 29 systematic reviews (Table S1 ). These reported results of 93 trials, and 537 outcomes.
Randomised trials
We identified 93 randomised controlled trials. These trials together reported 1804 outcomes.
Registered trials
We identified about 60 progestogen trials included in one or more registries. Of these at least 30 were discontinued or remain unpublished (data not shown). Of the remainder three unblinded trials were registered during recruitment. [5] [6] [7] Four published trials were excluded because they had been registered after trial completion [8] [9] [10] [11] and two because they did not report the registered primary outcome 12, 13 (Table S2) . One trial registration NCT00830765 was used for two trials. 12, 13 The first a randomised controlled trial of progestogen for preterm premature rupture of membranes and the second a trial of progestogen in women with arrested preterm labour. The primary outcome was updated in the registry from "the aim is to compare progesterone to a placebo to ascertain if there is a reduction in preterm birth among patients receiving the active drug" to "weeks gestation at birth among patients receiving the active drug" after the first study had been published in 2013. Neither paper reported either of the two registered primary outcomes. Instead they reported "interval from study entry to delivery" and "delivery before 37 weeks" respectively. There were other inconsistencies between registry and publication versions. Both trials were excluded.
This left 22 randomised controlled trials with primary outcomes which were judged not to be at risk of P-hacking. (Table 1 ). The full list of unregistered trials identified is shown in Appendix S2.
We identified one trial via PubMed registered with the Iranian Registry of Clinical Trials. 14 We converted Persian calendar dates on the registry to Gregorian so they could be compared with the Gregorian dates in the published manuscript.
Study characteristics
Nineteen of twenty-nine meta-analyses concluded that progestogens were effective for a variety of indications (Table S1) .
Overall the 29 meta-analyses (MA) reported 537 MA outcomes together with 95% confidence intervals (CI). Of these 372 favoured progestogen, 154 favoured control and 3 had an exact RR of 1. Of the MA outcomes which favoured progestogen 113 (30%) had a CI which excluded 1, i.e. were nominally statistically significant. Of the MA outcomes which favoured control, 145 (94%) had a CI which included 1.
The unregistered and late registered trials had 1782 outcomes reported in the various systematic reviews. Of these 618 favoured progestogen, 378 favoured control and 32 had an exact RR of 1. Of the individual trial outcomes which favoured progestogen 116 (19%) had a CI which excluded 1, i.e. were nominally statistically significant. Of the individual trial outcomes which favoured control, 366 (97%) had a CI which included 1 (Table S3) .
Of the twenty-two included trials, 8113 participants were randomised. Nineteen trials reported data from 7125 patients evaluated the efficacy of progestogens in preventing or treating preterm birth [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] two trials (162 patients) studied the efficacy of progestogen in preterm pre labour rupture of membranes 33, 34 and one trial (826 patients) investigated the efficacy of progestogen in preventing recurrent miscarriage. 35 The route of progestogen administration was equally divided, with eleven studies using intramuscular injection and eleven by the vaginal route. Twelve trials were prospectively registered before enrolment of the first participant. Thirteen trials were registered after the first patient had been recruited, nonetheless all of these studies were double blind and registered before unblinding after either achieving their sample size or stopped for an unrelated reason.
Nineteen included trials reported a dichotomous primary outcome. Three studies reported continuous primary outcomes of either interval from inclusion until delivery 25, 27 or gestational age at birth. 28 
Synthesis of results
In our meta-analysis, restricted to trials reporting predefined primary registered outcomes there was no effect of progestogen on. For dichotomous outcome RR 1.00 (95% CI 0.94-1.07) and continuous outcome RR À1.39 (95% CI À7.47 to 4.69). This was also the case when grouping trials by indication or when combining indications (Figures 2 and 3 ).
The number of secondary outcomes reported by each trial ranged from 2 to 103. These included outcomes relating to pregnancy, gestation at delivery, birthweight, maternal and neonatal morbidity. 
Discussion
Main findings
When evaluated in registered double-blind trials with analysis restricted to predefined primary outcomes, progestational agents in pregnancy are ineffective for all indications they have been tested for. One trial appeared to show a marginally significant result according to conventional tests of significance. 19 This could well be a chance effect, on average one out of 20 perfectly conducted randomised trials will show an effect at the conventional P = 0.05 level of statistical significance. We also found the two well known trials by Meis et al. 36 and Fonseca et al. 10 were unregistered and registered late respectively.
It was disappointing that we identified more systematic reviews of this drug in pregnancy (n = 29) than prospectively registered trials (n = 22). We hope readers will forgive us adding to the former number and that in future more research effort will be spent on well conducted primary research.
Strengths and limitations
The strength of this study is our restriction to those trials conducted with the highest methodological rigour. Although we may have missed some unregistered trials it is unlikely we missed any registered ones; by definition trials not found by our search of trial registries were unregistered. The limitations are that including different clinical conditions, gestations at treatment and outcomes, albeit all treated with the same drug, is of more methodological than clinical significance. Nonetheless, we did not extract all reported outcomes from these trials. We only report those outcomes which made it into a systematic review.
Some readers may question our combining trials testing the effect of progestogen in different settings. The included studies are heterogeneous in terms of indication, clinical characteristics, inclusion criteria, primary outcomes all of which can affect the results of this systematic review. We agree that this may not be biologically or scientifically plausible, but we did so because our aim is primarily methodological. We have shown that when opportunity for P-hacking is removed, with one exception which would be expected by chance, progestogen trials in pregnancy give negative results.
The International Committee of Medical Journal Editors (ICMJE) recommends that all medical journal editors require, registration of clinical trials in a public trials registry at or before the time of first patient enrolment as a condition of consideration for publication. Nonetheless, we also included trials registered during the recruitment phase. We reasoned that for a double blind trial, providing the blinding code had not been broken, this gave no opportunity for selective choice of outcome.
Interpretation
We chose not to present secondary outcomes and those from non-registered trials as the list would be too long. However, among 29 previous meta-analyses (Table S1 ), 19 concluded that progestogens are effective and a further review stated that it may be effective with a need for caution. Only seven reviews concluded that progestogen was ineffective. It is possible these conflicting findings are due to population differences or progestogen preparation. However, we believe the most likely reason for the difference is that many non-registered clinical trials silently switched outcomes. Without prospective trial registration it is impossible to prove this for any individual trial. The Centre for Evidenced-based Medicine Outcome Monitoring Project (COMPare) has been monitoring clinical trials for switched outcomes in the top five medical journals (NEJM, JAMA, The Lancet, Annals of Internal Medicine, BMJ) since October 2015. To date, comparing 67 trials with their protocol or registry they have found 300 outcomes were not reported and 357 outcomes silently added. 37 Our suggestion that progestogens are ineffective for preventing pre-term birth in general is likely to be widely accepted in light of the recent negative results from the high quality prospectively registered OPPTIMUM trial. 15 However, those who are tempted to suggest that progestogens work in singletons but not twins, that some types of progestogen work while others don't, that it works for prevention but not treatment, or in specific subgroups such as women with a short cervix, should think again. The evidence does not justify clinical use of progestogen, and we doubt it even justifies any more trials.
The exception is progestogen treatment for luteal phase support in assisted reproduction treatment. Despite all published systematic reviews suggesting that this is effective the evidence comes entirely from unregistered trials. A well conducted registered trial of progestogens for this indication is needed.
Conclusions
We believe by limiting meta-analyses to trials which cannot be P-hacked we have shown that selective outcome reporting is present in obstetrics and gynaecology. P-hacking is an important researcher-driven source of bias and through data driven meta-analyses its effects go beyond the interpretation of the original studies. Indeed the UK National Institute for Health and Care Excellence recommends progesterone for women with a short cervix at risk of preterm birth. 38 Clinicians and policy makers should be aware of this source of bias when making treatment decisions.
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